Join to View Full Profile
Mount Sinai School Of Medicine Of New York University One Gustav1 Gustave L Levy PlNew York, NY 10029
Dr. Rossi is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
New York Presbyterian Hospital (Cornell Campus)Fellowship, Hematology and Medical Oncology, 2010 - 2013
Sidney Kimmel Medical College at Thomas Jefferson University/TJUHResidency, Internal Medicine, 2007 - 2010
George Washington University School of Medicine and Health SciencesClass of 2007
Certifications & Licensure
FL State Medical License 2022 - Present
NY State Medical License 2010 - 2025
PA State Medical License 2007 - 2010
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013-2014
Clinical Trials
- BiRd vs. Rd as Initial Therapy in Multiple Myeloma Start of enrollment: 2016 Feb 01
- Radiotherapy With Immunotherapy for Systemic Effect in Myeloma (RISE-M) Start of enrollment: 2018 Oct 23
- Carfilzomib, Clarithromycin (Biaxin®), Lenalidomide (Revlimid®), and Dexamethasone (Decadron®) [Car-BiRD] Therapy for Subjects With Multiple Myeloma
- Join now to see all
Publications & Presentations
PubMed
- Universal driving restrictions beyond 4 weeks appear unnecessary following CAR-T therapy in multiple myeloma.Rahul Banerjee, Alicia Richards, Shonali Midha, Aimaz Afrough, Faiz Anwer
Blood Advances. 2025-03-15 - Impact of Prior Selinexor Exposure on Outcomes of Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Multiple Myeloma: An Exploratory Analysis.Bruno Almeida Costa, Danai Dima, Tomer Mark, Norah Layla Sadek, Stephen Ijioma
Journal of Clinical Medicine. 2025-02-16 - Delayed neutrophil recovery following BCMA CAR-T therapy in Duffy-null myeloma does not impact severe infections or survival.Zachary M Avigan, Saoirse Bodnar, Darren Pan, Jerrel Catlett, Joshua Richter
Blood Advances. 2025-01-14
Press Mentions
Mount Sinai Highlights Key Updates and Trends for Multiple Myeloma Awareness Month 2025March 3rd, 2025
First Patient Dosed with Off-the-Shelf UCARTCS1 Product Candidate for Relapsed/Refractory Multiple MyelomaNovember 20th, 2019
Treating Multiple Myeloma: Common Side Effects to Watch Out ForJuly 1st, 2019- Join now to see all
Professional Memberships
- Member
- Member
- International Kidney and Monoclonal Gammopathy Research GroupMember
- International Myeloma SocietyMember
Other Languages
- Portuguese, Spanish, French, Italian
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
